Quick answer
What does tissue repair research say about IGF-1 and IGF-1 LR3? Published work is mostly on native IGF-1, not LR3. In cultured muscle cells, IGF-1 signaling through PI3K/Akt/mTOR was reported to drive myotube hypertrophy; in mice, muscle-targeted IGF-1 expression was reported to sustain hypertrophy and regeneration in aged muscle; and in rats, IGF-1 and its variants, including an LR3-type analog, were reported to be anabolic under specific conditions. These are model-system findings. IGF-1 LR3 is relevant to this literature as a binding-protein-resistant ligand used to probe the pathway, and nothing here supports any claim outside laboratory research.
"Tissue repair" is a broad phrase, and for IGF-1 the supporting research is concentrated in a few model systems: skeletal muscle cells, genetically modified mice, and rodent studies comparing IGF-1 with its engineered variants. This article summarizes what those studies report, separates the findings about native IGF-1 from findings about the LR3 analog, and describes what a laboratory can and cannot infer. It reviews published model-system work only and does not describe any use of the compound outside the laboratory. For laboratory research use only; not for human consumption.
Why the question is framed around models
Repair and regeneration involve several processes at once: survival of existing cells, activation of progenitor cells, protein synthesis, extracellular matrix remodeling and inflammation. IGF-1 signaling touches several of them, which makes it a frequent subject of tissue-biology research. Because those processes cannot be separated in a living organism, researchers use simplified models, each of which answers a narrow question. The table lists the main model types seen in the IGF-1 literature.
| Model type | What it isolates | Example from the literature | Main limitation |
|---|---|---|---|
| Cultured myotubes | Growth signaling in muscle cells without systemic factors | Rommel et al. (2001): IGF-1-induced myotube hypertrophy and its dependence on PI3K/Akt/mTOR and GSK3 pathways | No tissue architecture, blood supply or immune cells |
| Transgenic mice | Effect of sustained local IGF-1 expression | Musarò et al. (2001): localized Igf-1 transgene expression in muscle and its effect on senescent muscle | Lifelong expression differs from acute exposure |
| Gene delivery in mice | Effect of viral expression of IGF-1 in muscle | Barton-Davis et al. (1998): viral expression of IGF-1 and aging-related loss of muscle function | Vector effects; delivery varies |
| Rodent studies with IGF-1 variants | Comparison of native IGF-1 and binding-protein-resistant variants | Tomas et al. (1992, 1993): anabolic effects in dexamethasone-exposed and normal rats | Systemic delivery; species-specific |
No single model answers the whole question, and the pattern across them is more informative than any one result.
Cultured muscle cells: signaling that grows myotubes
In differentiated muscle cells, IGF-1 activates the IGF-1 receptor, IRS proteins and the PI3K/Akt cascade. Rommel and colleagues (2001) reported that IGF-1-induced hypertrophy of skeletal myotubes was mediated by PI3K/Akt/mTOR and PI3K/Akt/GSK3 pathways, with experiments that blocked individual pathway nodes to show where the response depends on them. A review by Schiaffino and Mammucari (2011) summarizes genetic mouse models showing how the IGF1–Akt axis regulates muscle growth. This is the part of the literature closest to what a cell-culture laboratory does with IGF-1 LR3, because the analog's binding-protein resistance suits low-serum myotube cultures where native IGF-1 can be captured by secreted binding proteins. The signaling steps are described in the research overview.
Transgenic and gene-delivery mouse work
Two mouse studies are often cited. Barton-Davis and colleagues (1998) used viral delivery of IGF-1 to muscle and reported that the aging-related loss of muscle function was blocked in the model. Musarò and colleagues (2001) reported that localized expression of an Igf-1 transgene in muscle sustained hypertrophy and regeneration in senescent muscle. Both used native IGF-1 (a locally expressed Igf-1 transgene in the second case), not the LR3 analog, and both manipulated expression within the tissue rather than adding the protein to the circulation. They show that sustained local IGF-1 signaling is sufficient to alter muscle behavior in those models. They do not show that adding IGF-1 or an analog from outside would do the same, and they cannot be read as evidence about any compound sold as a reagent.
Rodent studies with IGF-1 and its variants
The studies that bring the LR3-type analog into the picture are rodent comparisons. Tomas and colleagues (1992) reported that IGF-1, and especially IGF-1 variants with reduced binding-protein affinity, were anabolic in dexamethasone-exposed rats, a model of catabolic stress. A follow-up in normal female rats (Tomas et al., 1993) compared IGF-1 with a variant in animals not under that stress. The pattern is consistent with the view that binding proteins limit native IGF-1 and that variants which escape them are more potent, though the papers should be read for what each measured. Those papers describe growth and protein-balance measures in the animals as reported by the authors and should be read in full for the exact design, route and endpoints. They are animal studies with their own ethical and design requirements, and nothing in them is guidance for any other use.
What the pattern suggests, and what it does not
Across the models, IGF-1 signaling is consistently linked to muscle-cell growth and survival signals, and the engineered variants are reported to be more potent where binding proteins are abundant. What the pattern does not provide is a mechanism-to-outcome chain for tissue repair in general. Repair in different tissues involves different cell types, and results from muscle do not carry over to tendon, skin, nerve or bone. Short-term anabolic readouts are also not the same as functional regeneration, and acute stimulation can differ from sustained expression. A careful summary is that the model-system literature supports IGF-1 signaling as a regulator of muscle-cell growth pathways, and that variants such as LR3 are useful tools for probing it.
Designing a cell-culture experiment in this area
If the question is about signaling in a muscle or other repair-relevant cell culture, the following design points follow from the studies above.
- Use a defined readout (phospho-Akt, phospho-S6, myotube diameter or protein synthesis) with a time course.
- Include native IGF-1 and IGF-1 LR3 arms in the same experiment so the binding-protein effect is visible.
- Add pathway inhibitors for PI3K, mTOR and MEK to assign the response to a branch, as in Rommel et al. (2001).
- Document serum content and secreted binding proteins in the medium.
- Prepare stocks with the formula in the volume calculation guide, confirm concentration and keep single-use aliquots (see storing research peptides).
- Verify the lot, since folding and aggregation affect activity (see the purity testing guide).
Evidence at a glance
The following summary separates what each source type can support.
| Question | Supported by | Not supported by |
|---|---|---|
| Does IGF-1 signaling drive growth pathways in muscle cells? | Cultured myotube studies and genetic mouse models | Any statement about other tissues |
| Does sustained local IGF-1 expression alter muscle in aged mice? | Transgenic and viral-delivery mouse studies | Whether externally added protein does the same |
| Are binding-protein-resistant variants more potent than native IGF-1 in rats? | Rat comparison studies with IGF-1 variants | Potency in other species or conditions |
| Is the LR3 analog useful for low-serum cell culture? | Its design and widespread laboratory use | Any outcome beyond the culture model |
Reading the table as a guide to the strength of each claim keeps the literature in proportion.
The reagent
The IGF-1 LR3 product page lists a 1 mg lyophilized powder in a sealed clear glass vial, HPLC purity of 98% or higher, and storage at 2–8 °C with −20 °C for long-term holding, protected from heat, moisture and light. Certificates, where published, are in the COA library. The reconstitution calculator handles the unit conversions. For the structural background, see IGF-1 LR3 explained and the comparison with IGF-1 DES.
Reading claims about repair critically
Search results on this topic often mix model-system findings with claims that go beyond them. When you see a statement about repair, check which molecule was studied, in what species or cell type, by what route, with what readout and how large the effect was, and whether the claim is made by the authors or added by a summarizer. A claim that cannot be traced to a primary paper with those details should be regarded as unsupported. The same discipline applies to this article: each study above is cited so the original can be read, and anything not in those abstracts has been left out.
Related reading
- IGF-1 LR3 product page
- IGF-1 LR3 research overview
- IGF-1 LR3 explained
- IGF-1 LR3 vs IGF-1 DES
- IGF-1 LR3 purity testing
- Storing research peptides
- Reconstitution calculator
- COA library
Frequently asked questions
Is there research on IGF-1 LR3 specifically in tissue repair?
Direct studies of the LR3 analog in repair models are limited. Most of the literature concerns native IGF-1, with a few rodent studies comparing IGF-1 variants.
What do muscle-cell studies report?
That IGF-1 signaling through PI3K/Akt/mTOR and GSK3 pathways was reported to mediate myotube hypertrophy in cultured skeletal muscle cells.
What do the transgenic mouse studies show?
That sustained local IGF-1 expression in muscle was reported to maintain hypertrophy and regeneration in aged mouse muscle, and viral delivery was reported to block aging-related loss of muscle function in the model.
Do those studies use the LR3 analog?
No. They used native IGF-1. The analog appears in separate rodent comparisons and in cell-culture use.
Why are binding-protein-resistant variants relevant?
Because binding proteins limit native IGF-1 in many systems. Variants that escape them were reported as more potent in the rat studies.
Can results from muscle be applied to other tissues?
Not automatically. Different tissues involve different cell types and signals, so each needs its own evidence.
Is a cell-culture result evidence of regeneration?
No. It shows that signaling or growth responses can be triggered under defined conditions, not that regeneration occurs in an organism.
What controls should a pathway experiment include?
A native IGF-1 arm, pathway inhibitors for PI3K, mTOR and MEK, a receptor-blocking arm and matched vehicle and carrier controls.
How should the reagent be prepared?
Reconstitute gently, calculate concentration from mass and volume, confirm it, and keep single-use aliquots. See the handling articles linked above.
Does this article make claims beyond the laboratory?
No. It summarizes published model-system research and is for laboratory research use only.
Related reading: IGF-1 LR3 vs Des(1-3) IGF-1: Choosing an Assay Analog, IGF-1 LR3 vs Standard IGF-1: Binding Proteins in Culture, IGF-1 LR3 Half-Life: What Published Studies Report.
References
- Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 2001;3(11):1009-1013. doi:10.1038/ncb1101-1009
- Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle. 2011;1:4. doi:10.1186/2044-5040-1-4
- Musarò A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27(2):195-200. doi:10.1038/84839
- Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA. 1998;95(26):15603-15607. doi:10.1073/pnas.95.26.15603
- Tomas FM, Knowles SE, Owens PC, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J. 1992;282:91-97. doi:10.1042/bj2820091
- Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993;137(3):413-421. doi:10.1677/joe.0.1370413
- Hakuno F, Takahashi SI. 40 years of IGF1: IGF1 receptor signaling pathways. J Mol Endocrinol. 2018;61(1):T69-T86. doi:10.1530/jme-17-0311
